NOVELTIES IN DERMATOLOGY

Treatment of Cutaneous Lymphomas: an Update

R.M. Izu-Belloso, a,* J.C. García-Ruiz b

a Servicio de Dermatología, Hospital de Basurto, Bilbao, Spain
b Servicio de Hematología y Hemoterapia, Hospital de Cruces, Barakaldo, Bizkaia, Spain

Received 10 August 2011; accepted 29 January 2012
Available online 26 September 2012

Abstract Primary cutaneous lymphomas (PCLs) are a heterogeneous group of lymphoid tumors that originate primarily in the skin. Most PCLs (75%) are T-cell lymphomas and only 20% to 25% involve B cells. It is important to differentiate between cutaneous lymphomas and lymph node tumors given the differences in their molecular biology and clinical, histopathologic, and immunophenotypic features. Moreover, PCLs generally follow a more indolent course and require different treatments.

Many treatment options are available for managing PCL’s. The choice should be based primarily on the clinical stage of disease but must also take into consideration other factors, such as the patient’s age and general health, the availability and accessibility of the treatment, and the cost-benefit ratio. It will be important to use a multidisciplinary approach, involving a team of expert dermatologists, hematologist-oncologists, and radiotherapists who are familiar with this rare disease. Recent years have seen the emergence of many new therapies, particularly for advanced stages of the disease and for patients whose tumors have proven refractory to treatment. The objective of this article is to review all the treatment options available to us.

PALABRAS CLAVE Linfoma cutáneo; Tratamiento; Actualización; Revisión

Resumen Los linfomas cutáneos primarios (LCP) constituyen un grupo heterogéneo de neoplasias linfoides que se originan primariamente en la piel. La mayoría (75%) son linfomas de células T y solo un 20-25% se originan a partir de los linfocitos B. Es importante diferenciar los LCP de sus equivalentes ganglionares, dado que presentan características clínicas, histopatológicas, inmunofenotípicas y de biología molecular diferentes con un pronóstico en la mayoría de los casos más indolente y tratamientos diferentes.

Existen múltiples opciones terapéuticas en el manejo de los LCP. La elección del tratamiento debe basarse principalmente en el estadio clínico del paciente, pero deben considerarse también otros factores, como la accesibilidad a los tratamientos, la edad y el estado general del paciente o el coste-beneficio. Además es importante el abordaje multidisciplinar de estos pacientes, formando un equipo experto entre dermatólogos, hemato-oncólogos y radioterapeutas que conozcan bien esta infrecuente patología. En los últimos años asistimos a la aparición...
Introduction

Primary cutaneous lymphomas (PCLs) are a heterogeneous group of lymphoid malignancies that originate primarily in the skin.1 Most (75%) are derived from T cells (primary cutaneous T-cell lymphoma [CTCL]) while 20% to 25% are derived from B cells (primary cutaneous B-cell lymphoma [CBCL]). Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common such PCLs. It is important to differentiate PCLs from their equivalent lymph node disease, given that they show clinical and histopathologic differences and have different immunophenotypes and a different molecular biology. Most importantly, PCLs have a more indolent course in most cases and different treatment regimens are used.

For a correct diagnosis and hence appropriate treatment, it is necessary to be familiar with the latest classifications such as those of the European Organisation for Research and Treatment of Cancer (EORTC)/World Health Organization (WHO)1 (Table 1) and the WHO (2008).2,3 PCLs have a very low incidence,4 and most patients survive for a long time. It is therefore difficult to assess the impact of a given treatment on outcome and there are almost no case-control studies to guide us. The levels of evidence are therefore low. Ideally, all patients with PCLs would be included in a clinical trial.

Many therapeutic options are available for the management of PCL.5,6 The choice of treatment should be based mainly on the clinical stage, but other factors should also be considered such as access to treatments, age and general health of the patient, and cost-benefit ratio. In the initial stages of the disease, no data are available to demonstrate the superiority of systemic treatment (the more aggressive option) over local treatment targeting the skin lesions. A conservative approach is therefore recommended.

The treatments can be divided into 2 broad groups:

1. Treatments that target the skin and act only on the population of neoplastic cells in the skin. In this case, the adverse effects are usually less severe than those arising with systemic treatments. This type of treatment is in practice the only one recommended for first-line treatment of early phases of MF. In advanced stages, it is still an important option, forming part of combination therapies. Such treatments include:
   - Topical corticosteroids
   - Alkylating agents: topical nitrogen mustard (methyloretamine) and carmustine
   - Narrow-band UV-B phototherapy, psoralens + UV-A (PUVA), and other types of phototherapy
   - Radiotherapy (conventional and electron beam)

2. Systemic treatments, which include biological response modifiers (such as retinoids, cytokines, immunotoxins and vaccines, monoclonal antibodies, and histone deacetylase inhibitors), chemotherapies (traditional single- or multiagent chemotherapy or polychemotherapy, new chemotherapies), and allogeneic stem cell transplantation.

Treatments That Target the Skin

Topical Corticosteroids

Corticosteroids are able to induce apoptosis in most neoplastic lymphocytes in the skin and reduce the number of Langerhans cells, thereby interfering with the stimulation of neoplastic cells. Although such treatments have been in
use for years, there are few studies of their use.\textsuperscript{7,8} Zack-
heim et al.\textsuperscript{9} reported their experience in 79 patients with
MF in the form of patches or plaques. Patients received medium-
and high-potency corticosteroids (class I-III), some-
times with an occlusive dressing. In patients with stage T1
disease, 63\% had complete response (CR) and 31\% had par-
tial response (PR), while in patients with stage T2 disease,
25\% had CR and 57\% had PR. The adverse effects observed
were adrenal suppression in 10 patients, skin irritation in 2,
and skin atrophy with stretch marks in 1 patient. The authors
concluded that the treatment is well tolerated and effective
in the very incipient stages of the disease.

Alkylating Agents

Alkylating agents are drugs that act on different mechanisms
and functions of DNA, thereby finally inducing cell death.

Topical Mechlorethamine (Nitrogen Mustard)

Although the exact mechanism of action of
mechlorethamine is unknown, when administered system-
atically, it acts as an alkylating agent with an antimitotic
effect. Its topical activity, however, appears to be mediated
by immune mechanisms or by interaction with Langerhans
cells. The drug is usually used as an aqueous solution
with a strength of 10-20 mg/100 mL, or as a gel (10-20 mg/100 g
petroleum jelly).\textsuperscript{9-15} An ongoing randomized, double-blind,
multicenter trial is comparing the safety and efficacy of 2
preparations of nitrogen mustard (0.02\% in propylene glycol
and 0.02\% in petroleum jelly) in patients with stage I or IIA
MF refractory to topical corticosteroids.\textsuperscript{16} The preliminary
results have shown similar efficacy (overall response rate
[ORR] of around 70\%) and a good safety profile (no systemic
absorption was seen) for both preparations. In clinical
practice, the drug is initially applied daily until the lesions
have cleared (in 3 to 6 months with the solution and 6
to 12 months with the gel). An intermittent maintenance
regimen is followed thereafter. Application to the entire
body surface is usually recommended, though avoiding
intertriginous areas. However, the need to treat unaffected
areas is not very clear. Response varies between 50\% and 75\%
in stage T1 and 25\% and 50\% in stage T2. Contact dermatitis
(allergic or irritant) may arise, particularly when using the
aqueous solution (30\% vs < 5\% with the gel). Urticaria and
anaphylactic reactions have also been reported. Prolonged
use increases the risk of nonmelanoma skin cancer, particu-
larly if the patients have received prior PUVA or total skin
electron beam therapy. In general, myelosuppression or
other systemic effects do not occur. Efficacy appears to be
similar for the 2 preparations (solution and gel), although
prospective studies comparing the 2, other than the one
described above,\textsuperscript{16} have not been undertaken. In recent
years, the availability of mechlorethamine in hospital
pharmacies has been limited, and so it is unfortunately
being used less and less despite its efficacy.

Carmustine

Carmustine is an alkylating agent that induces cell death
through inhibition of DNA synthesis. It is used as an alco-
hol solution (2 mg/mL) or as an ointment.\textsuperscript{17-20} It should be
applied daily to the lesioned skin, and the clearance time
is similar to that of mechlorethamine. Response rates vary
from 86\% in stage T1 to 48\% in stage T2. Most patients
experience erythema, sometimes followed by persistent
telangiectasia, and approximately 3\% to 5\% develop mild
leukopenia due to myelosuppression. The agent can be
used as an alternative in patients who are allergic to
mechlorethamine, although the availability of carmustine
is also limited.

Phototherapy

Narrow-Band UV-B Phototherapy (311-312 nm)

Several studies have shown the usefulness of narrow-band
UV-B phototherapy in the initial stages of MF (CR rates
of around 75\%, with a mean response duration of 51
months).\textsuperscript{21-26} The risk of skin cancer is increased, however,
and therapy is only effective in MF with incipient lesions
with little or no infiltration, given the limited penetration
of the radiation. This type of therapy is considered particu-
larly useful in those patients who do not tolerate psorales, those
with very light skin, and those with very incipient lesions.\textsuperscript{27}

Psoralens Plus UV (320-400 nm)

PUVA is the classic treatment in the early stages of lymphatic
disease.\textsuperscript{20,29-34} Usually, the patient starts with 2 to 3 weekly
sessions, with the interval between sessions being reduced
according to response. There is no consensus about whether
it is necessary to follow a maintenance regimen once CR has
been achieved.\textsuperscript{35} In a study of 82 patients with MF in the
form of superficial plaques and/or palpable plaques, CR was
obtained in 65\% and PR in 30\%, with a mean response dura-
tion of 43 months.\textsuperscript{28} Chronic actinic damage was observed
in 10\% of the patients, with the appearance of carcinomas
in 6 patients: 3 with basal cell carcinoma and 3 with squa-
mous cell carcinoma. Although there are studies that show a
statistically significant increase in carcinogenesis, includ-
ing melanoma, we believe that this risk is more theoretical
than real, at least in this group of patients. According to
the most recent studies, the disease-free interval is related
to a higher cumulative dose of PUVA and longer treatment
times.\textsuperscript{35,36} Although late recurrences are seen, between 30\% and
50\% of patients in stages I, IB, and IIA can maintain CR
for periods of up to 10 years. The disease-free survival at 5
and 10 years for patients in stage IA was 56\% and 30\%, respec-
tively. For those patients in stages IB/IIA, 5- and 10-year
disease-free survival was 74\% and 50\%, respectively. How-
ever, the overall survival did not vary significantly between
those with recurrences and those without.

Others Types of Phototherapy

- Extracorporeal photopheresis.\textsuperscript{36-39} In a modification of
PUVA, after ingestion of psorales, circulating mononuclear
cells from the patient are exposed to UV-A. The main
drawback of this approach is the high cost and, in addi-
tion, efficacy is no better than other treatments. The
best responses are obtained in patients with early-stage SS
who have normal CD8 counts and have not received prior
aggressive therapies.
- **Hypericin.** This new photodynamic plant derivative induces T-lymphocyte apoptosis in association with visible or UV-A light. If preliminary results are confirmed, this option could be better than the other forms of phototherapy, as visible light does not increase the risk of skin cancer.

- **Photodynamic therapy.** The use of photodynamic therapy with derivatives of 5-aminolevulinic acid could be particularly appropriate in patients with few lesions or lesions on the scalp.

- **Monochromatic excimer laser light.** Excimer lasers at a wavelength of 308 nm have also been used and are approved by the US Food and Drug Administration (FDA) for psoriasis and vitiligo. Passeron et al. have performed a clinical trial in which good responses were obtained in very incipient lesions. This approach can therefore be considered in areas that are not usually accessible with phototherapy.

The evidence to support these approaches is, however, limited. Likewise, there is little evidence with regard to other therapeutic options.

### Radiotherapy

**Conventional (Orthovoltage)**

Conventional radiotherapy is used for highly infiltrated plaques or localized MF tumors refractory to other treatments. It is particularly indicated as front-line treatment of cutaneous marginal area B-cell lymphoma and follicle center lymphoma along with excision. The recurrence rate is higher if doses less than 30 Gy are used. Local radiotherapy has also been used in solitary MF lesions with impressive results.

**Total Skin Electron Radiation (Electron Beam Therapy)**

An electron beam is the treatment of choice for patients with MF with infiltrated plaques or small generalized tumors. The most widely used voltage is 6 MeV, and therapy is applied 4 days per week for a total dose of 3600 cGy in 10 weeks. The treatment can be repeated several times if reduced doses are used. Adverse effects include generalized erythema, edema, scaling and exudation, apparent worsening of existing lesions, total loss of skin appendages, transverse melanonychia and, less frequently, blistering. Hair loss is usually reversible if the total dose administered has not exceeded 2500 cGy. In the longer term, patients may develop edema, hyperpigmentation, telangiectasia, and persistent xerosis, while men may become sterile.

The disease-free interval can be extended according to some authors by subsequent maintenance therapy, either with mustard derivatives or PUVA.

**Systemic Treatments**

**Biological Response Modifiers**

**Retinoids**

Isotretinoin and etretinate have been used in the treatment of MF to similar effect. Their usefulness as monotherapy is limited, as it was seen that atypical cells were still present according to the pathology study even though the lesions had apparently healed. These agents have been combined with PUVA and interferon alfa (IFN-α). When combined with PUVA, they seem to be able to reduce the UV-A dose while with IFN-α they seem to enhance the response to interferon in early but not late disease stages. However, there are no randomized studies that compare IFN-α and IFN-α in combination with retinoids.

Bexarotene is a new retinoid (more specifically a retinoid) whose exact mechanism of action is unknown although it inhibits growth of tumor lymphocytes and also enhances apoptosis in vitro. Bexarotene selectively activates RXR receptors (a type of nuclear receptor activated by retinoic acid), acting as a regulator of cell differentiation and proliferation. In 2002, the FDA approved the compound, both for topical use as a 1% gel (which has so far not been marketed in Spain but can be obtained as an imported medicine) and for systemic use at an optimum dose of 300 mg/m²/day. Regular laboratory testing should be performed during treatment, focusing mainly on triglyceride levels and thyroid hormones. Bexarotene induces hypertriglyceridemia, which can be marked at times. Preventive treatment should therefore be given the preceding week with statins or a fenofibrate but not with gemfibrozil as this fibrate increases the levels of bexarotene in blood, probably through inhibition of cytochrome P450. Hypothyroidism is another common adverse effect that can be controlled with administration of thyroid hormone. Bexarotene can be combined with other treatments such as PUVA or IFN-α. It may also find uses in a maintenance regimen after more aggressive therapies in patients with more advanced disease. As with other retinoids, it requires contraceptive measures in view of the risk of malformations.

**Interferon-alfa**

IFN-α is used as monotherapy administered subcutaneously (although intramuscular and intralional administration is also possible) at a dose of 3 to 20 million units per day, 3 days a week, with a good (dose-dependent) response, particularly in early-stage disease (ORR of approximately 70%) or in combination with other therapies such as PUVA (apparently the most effective combination), retinoids, or purine analogs (fludarabine) with apparent benefit (studies that compare these options with IFN-α monotherapy are lacking).
Adverse effects include flu-like syndrome, gastrointestinal disorders, bone marrow suppression, and elevated transaminases. The agent can be used for years as maintenance in patients who showed a good response and are at risk of relapse, although there is a risk of developing autoimmune diseases such as diabetes mellitus, thyroiditis, or hemolytic anemia.65–67

Immunotoxins
Denileukin diftitox (DAβ389-interleukin 2 [IL-2]) is the first fusion cytotoxin approved by the FDA for the treatment of CTCL.68,69 It acts as a specific cytotoxin for cells that express the IL-2 receptor. It is obtained by expression in Escherichia coli of the product of fusion of the human IL-2 receptor genes with cytotoxic sequences of diphtheria toxin. The agent binds to the IL-2 receptor (CD25) of T lymphocytes, thereby inhibiting protein synthesis, and is administered intravenously at a dose of 9 or 18 mg/kg/d in 5-day cycles every 3 weeks. It has been shown to be particularly effective in stage IIB MF (response rate, 38%). Transient flu-like syndrome is reported in 60% to 70% of the patients, a similar figure to that seen with IFN-α. Other adverse effects such as urticaria, anaphylaxis, or vascular leak syndrome have also been reported. Some patients developed anti-DAβ389 or anti-IL-2 antibodies in the first cycle, but there was no correlation with either toxicity or response. Efficacy has been boosted in recent studies through the concomitant use of oral bexarotene, particularly in patients with low or nonexistent expression of the IL-2 receptor.67,68 Combination therapy enabled lower doses of the 2 treatments to be used. The agent has been used in monotherapy in CTCLs other than MF,69 and in combination with radiotherapy.70

Monoclonal Antibodies
Alemtuzumab. Alemtuzumab is a humanized monoclonal antibody that targets the CD52 glycoprotein expressed on the surface of T and B lymphocytes, natural killer (NK) cells, and to a lesser extent on monocytes and macrophages. The mechanism of action has not been fully elucidated but involves direct complement-mediated cell lysis and also antibody-dependent cytotoxicity and apoptosis. In 2003, its usefulness was demonstrated in 22 patients with pretreated MF/SS, most of whom had advanced disease (86% ≥ stage III and 36% with B symptoms) and a general poor state of health. The ORR was 55% (32% CR) and the mean response duration was 12 months.71 Recently, these encouraging outcomes have been reproduced.72 Alemtuzumab-induced cytopenia is potentially the most serious complication reported. Although different degrees of anemia and/or thrombocytopenia may develop due to mechanisms that are not well understood, T- and B-cell lymphopenia is a generalized finding in all patients. This predisperses them to serious opportunistic infections (particularly by cytomegalovirus and Pneumocystis jiroveci).73 Alemtuzumab seems especially useful in the management of pruritus associated with the erythrodermic forms (SS).74,75

Zanolimumab. Zanolimumab is another monoclonal antibody, which targets the CD4 receptor expressed on T lymphocytes and macrophages. It interferes with T-cell activation by impeding the interaction of CD4 with class II molecules of the major histocompatibility complex and also induces cell lysis through antibody-mediated cytotoxicity rather than by complement-mediated effects as is the case with alemtuzumab.76,77 Zanolimumab has been shown to be effective in 2 phase II multicenter studies of 47 patients with heavily pretreated persistent and refractory CTCL (38 MF and 9 SS).18 The arms in which high doses of zanolimumab were administered (560 mg/wk for early stages [MF, stages IB-IIA] and 980 mg/wk for advanced stages [MF, stages IIb-IVB, and SS]) achieved an ORR of 56% with an impressive mean duration of response of 81 weeks (particularly in MF). Overall, zanolimumab has an acceptable safety profile with moderate adverse effects such as dermatitis, eczemas, and infections limited to the skin and upper respiratory tract despite the severe CD4 cell depletion associated with its use. No differences were observed in the incidence of infection between the 2 different dose groups. Although a more marked CD4 cell depletion was observed among patients treated at the higher dose (560-980 vs 280 mg/wk), of note was that there were no statistically significant differences in CD4 cell recovery once treatment had finished. On the basis of these findings, a pivotal phase III study was started and is currently in progress.

Rituximab. Rituximab is a chimeric (human-murine) anti-CD20 monoclonal antibody that is used as monotherapy or in combination with other agents mainly for the treatment of systemic non-Hodgkin B-cell lymphoma. Several studies have found it to be effective when administered intravenously in patients with CBCL (marginal zone and follicle center cell types).45,46,79,80 It is considered particularly useful in patients with multiple lesions or those with a high risk of recurrence, as well as in areas where we wish to avoid the unsightly sequelae of surgery and/or radiotherapy. It is also used in combination with cyclophosphamide, vincristine, and prednisone with doxorubicin (CHOP) for CBCL, leg-type.

Histone Deacetylase Inhibitors. Histones are proteins present in abundance in cell nuclei, where they form the chromatin of eukaryotic cells along with other types of proteins and DNA. In recent years, several molecules within the pharmacologic group of histone deacetylase inhibitors have been developed, encouraged by different experimental findings that suggest that excess histone acetylation occurs in most cancers.81,82 Four histone deacetylase inhibitors have been studied in the treatment of CTCL: vorinostat, romidepsin, panobinostat, and belinostat.

Vorinostat. Vorinostat has been authorized by the FDA for the treatment of skin manifestations of patients with CTCL which persist, progress, or recur after at least 2 systemic treatments.83 However, the drug has not been marketed in Europe. The indication was established after a phase II study of 74 patients with MF/SS.84 Most of these patients had advanced disease stages (61 patients with ≥ IIB disease and 30 patients with SS, while 22 patients had clinically abnormal lymph nodes). All patients had received intensive treatment (96% with bexarotene, 63% with IFN-α, 61% with chemotherapy, 36% with photopheresis, and 31% with denileukin diftitox). The dose was 400 mg/d, administered orally, with adjustment or suspension according to toxicity or adverse effects. Overall, 29.7% achieved response. Among patients with advanced disease (IIB or worse), 29.5% achieved response. Among patients with SS, 33.3% achieved
response. Vorinostat was generally well tolerated and the adverse effects observed most frequently were gastrointestinal (nausea, diarrhea) and constitutional (asthenia, anorexia, and weight loss). Cytopenias (thrombocytopenias and anemia) were also frequently reported. Neutropenia was not observed. Fewer than 15% of the patients required a reduction in vorinostat dose and 11% had serious adverse effects, which were mainly thrombocytopenic phenomena. QT prolongation was only observed in 3 patients.

Recent studies are using these agents in combination with other therapies such as bexarotene or IFN-α.86

**Romidepsin.** Romidepsin is a new and potent histone deacetylase inhibitor that has been used in patients with CTCL and peripheral T-cell lymphomas. Several studies have demonstrated its usefulness,87-90 with an ORR of 41% (7% with CR and 33% with PR), a median response duration of 14.9 months, and a median time to progression of 8.3 months. The most frequently observed adverse effects were nausea, asthenia, and vomiting. Adverse effects grade 3 or worse were only observed in 33% of the patients. The most frequently observed adverse effects were disease progression (6%), fever (3%), sepsis (2%), tumor lysis syndrome (2%), and hypotension (2%). Six patients died, one possibly of treatment-related causes. QT prolongation was only observed in 2% of the patients (patients with significant cardiac abnormalities and/or those in treatment with QT prolonging agents or inhibitors of cytochrome P3A4 were excluded from the study).

**Panobinostat.** The new histone deacetylase inhibitor, panobinostat, not only produces histone acetylation but also induces p21, cell cycle arrest, apoptosis, and HSP90 (pan-histone deacetylase inhibitor) acetylation. Its usefulness and safety profile have been demonstrated recently in a phase II study performed in 40 patients with CTCL refractory to at least 2 prior treatments (mean of 5 prior treatments per patient).91 Patients received 20 mg/d of panobinostat orally on days 1, 3, and 5 of each week until disease progression or intolerance. The response rates were poor. In patients who had received prior treatment with bexarotene (group 1, 25 patients), PR was obtained in 3 and 4 had stable disease. Three patients had progression. Thirty patients could not be evaluated because of limited follow-up at the time of publication. The most frequently observed adverse effects were diarrhea, thrombocytopenia, fatigue, asthenia, hypertriglyceridemia, taste alterations, nausea, and pruritus (15% of all patients). No significant QT prolongations were observed.

**Belinostat.** Belinostat is another pan-histone deacetylase inhibitor that has been tested in a phase II clinical trial with 29 patients (15 with MF, 7 with SS, 5 without either MF or SS, and 2 with unclassified disease).92 The participants received 1000 mg/m² in a 30-minute infusion from day 1 to 5 of each cycle, every 3 weeks. Seventeen patients achieved stable disease for longer than 127 days. There were 2 PR and 2 CR with a median response duration of 273 days. It is important to note that the time to response was very short: 16 days (range, 14-35 days) with a substantial improvement in pruritus. There were no reports of grade 4 hematologic toxicity or cases of grade 3 QT prolongation. Four grade 3 or 4 adverse effects were observed: pruritus, erythema, edema, and adynamic ileus.

**Others Bortezomib.** Bortezomib is a drug indicated as first-line treatment in patients with multiple myeloma who are not candidates for hematopoietic stem cell transplantation and in patients with a relapse after prior treatment. The group at the Hematology Institute of the University of Bologna in Italy conducted a phase II study of 12 patients (10 with advanced MF and 2 with peripheral T-cell lymphomas with isolated cutaneous involvement).93 They reported an ORR of 67%, including 2 CR (17%) and 6 PR (50%). One patient with MF and 1 with peripheral T-cell lymphoma achieved CR (10% and 50%, respectively). CR lasted for more than 1 year after the last study dose in the patient with MF while relapse was observed 10 months later in the patient with peripheral T-cell lymphoma. The regimen of bortezomib used was the same as for multiple myeloma: 1.3 mg/m², given intravenously on days 1, 4, 8, and 11 of each 21-day cycle up to a total of 6 cycles. The adverse effects observed most frequently were neutropenia (2 patients [17%), WHO grade 3), thrombocytopenia (2 patients [17%), WHO grade 3), and sensory neuropathy (2 patients [17%), WHO grade 3). No infections or treatment-related deaths were reported during the study. The rationale for using bortezomib is that it can act as an inhibitor of nuclear factor κB (NF-κB), which is constitutively activated in CTCL cell lines, and induce apoptosis.94 NF-κB is a transcriptional factor implicated in the generation of inflammatory responses, regulation of the cell cycle, and protection against apoptosis.

**Lenalidomide.** The antitumor effects of lenalidomide are attributed to several mechanisms of action: inhibition of the production of proinflammatory mediators by monocytes (tumor necrosis factor α, IL-1, IL-6, IL-12), enhancement of IL-2 and IFN-γ production by T lymphocytes, and enhancement of the cytotoxic activity of these cytokines and NK cells. In a phase II study, lenalidomide was administered at a dose of 10 to 25 mg/d for 21 days in cycles of 28 days to 25 patients with extensively pretreated CTCL (mean of 6 prior regimens).95 Seven patients achieved PR after a mean of 9 cycles of treatment. The adverse effects observed most frequently were anemia, scaling, pruritus, and leg edema. In the high-dose group, intense neutropenia was observed in 2 patients while 1 patient discontinued treatment due to dysarthria.

**Chemotherapy**

Chemotherapy should only be used in CTCL in advanced stages of the disease, as it is no more effective than conservative treatment in the early phases. Almost all chemotherapy agents used for systemic lymphomas have also been used in advanced CTCL: alkylating agents, methotrexate, cisplatin, etoposide, bleomycin, vinblastine, cyclophosphamide. It is not clear whether one agent is any better than another and, in general, responses are short-lasting. The most effective combination, and therefore the most widely used one, is CHOP or CHOP without doxorubicin (CVP), but randomized studies have not been undertaken that demonstrate increased survival with any of these regimens.

**Methotrexate**

Methotrexate is the first-choice treatment in CD30+ CTCL, particularly when the patient has multiple lesions.
(radiotherapy is the best alternative in solitary lesions). High weekly doses are required in some cases to achieve CR, with a higher risk of adverse effects.

Recently, 2 other chemotherapies (gemcitabine and pegylated liposomal doxorubicin [DOX-PEG]) have been shown to be useful in monotherapy.

**Gemcitabine**

Gemcitabine is a pyrimidine antimetabolite indicated for solid tumors traditionally considered resistant to conventional treatment such as lung cancer, ovarian cancer, pancreatic cancer, and urinary bladder cancer. Its effectiveness in cutaneous lymphomas has been investigated in 2 studies. The first to these was a series of 32 patients (mostly with MF). CR was achieved by 22% (7 patients) while PR was achieved by 53% (17 patients). Unfortunately, the study used standard criteria for assessing response as if the patients had common forms of non-Hodgkin lymphoma and not specifically cutaneous lymphoma (severity-weighted assessment tool). Response was achieved by 73% of those with MF (26 patients), with 23% with CR and 50% with PR. The only patient included with SS did not respond. The median duration of CR was 10 months (range, 4-22 months). Gemcitabine was administered as an intravenous infusion at a dose of 1200 mg/m² for 30 minutes in cycles of 28 days (total of 6 cycles) on days 1, 8, and 15 of each cycle. The most frequently reported adverse effects were cytopenias. Reversible liver toxicity was the most frequently reported nonhematologic adverse effect (13 patients, 40%). No treatment-related deaths were reported. The second study was a series of 33 patients, most of whom had heavily pretreated MF (median of 5 prior regimens) (31 patients). Two patients had anaplastic CD30⁺ T-cell lymphoma. Compared to the first study, a higher dose of gemcitabine was used (1000 mg/m²) but the schedule of administration and number of cycles were the same. Response was assessed using variables that included the area of skin involved, size of lymph nodes, and peripheral blood cytometry. Response was achieved by 68% of the patients (2 with CR). Myelosuppression was the most frequently observed adverse effect (grade 3 in 8 of the 33 patients) and 2 characteristic hemolytic syndromes were diagnosed in patients with SS. Other adverse effects were elevated transaminase liver enzymes, mucositis, lethargy, fever, hydropigmentation, infusion-related maculopapular rash, and different types of cardiovascular events. Another more recent multicenter study reported similar outcomes to the studies already discussed, but with significantly greater toxicity.

**Pegylated Liposomal Doxorubicin**

DOX-PEG is approved for the treatment of advanced ovarian cancer, relapsed multiple myeloma after hematopoietic stem cell transplantation, and AIDS-associated Kaposi sarcoma. The usefulness of DOX-PEG has also been demonstrated in patients with CTCL in observational and retrospective studies. Recently, a prospective, multicenter study analyzed use of this agent in 25 patients with MF and/or SS in stages ≥ II refractory to at least 2 prior lines of treatment and in patients with CD30⁺ large-cell CTCL. DOX-PEG was administered intravenously every 4 weeks at a dose of 40 mg/m²/d for up to 8 cycles. An objective ORR of 56% was reported (14/25 patients with CR and 9/25 with PR). Response rates were high in patients with SS, with 6 of the 10 (60%) responding. One of these responses was a CR. Response rates were also high in transformed CTCL, and 50% of these responses were a CR. In general, more adverse effects were seen than in the previous studies, with 4 episodes of serious infection and some cardiac events. DOX-PEG has also been shown to have good activity in 5 CBCLs (1 with marginal zone disease and 4 diffuse large-cell lymphomas, leg-type) in an Italian phase II pilot study (dose of 20 mg/m² every 3 or 4 weeks). An impressive prolonged CR was obtained in 4 of these patients (80%). In another study published recently, excellent outcomes were obtained with DOX-PEG in combination with bleomycin, vinblastine, and dacarbazine (CBVD regimen) in 37 patients with advanced PCL, both of T-cell origin (19 patients) and B-cell origin (18 patients). CR rates of 88.8% and 100%, respectively, were obtained. Between 4 and 6 cycles of CBVD were administered in the group of CTCL whereas those with CBCL received between 2 and 6 cycles (with rituximab added to the chemotherapy: R-CBVD). The safety profile was good. Subsequent allogeneic hematopoietic stem cell transplantation was performed in 3 patients (2 with CTCL and 1 with CBCL).

**Other Chemotherapies**

**Forodesine.** Forodesine is a purine analog that inhibits purine nucleoside phosphorylase. Recruitment of patients with MF/SS with refractory disease in stages ≥ IB to a phase II pivotal study was completed in 2010. The preliminary results of this multicenter study have been published recently. The overall response rate was around 30%. The most frequently observed adverse effects were nausea, tiredness, edema, dyspnea, and urinary calculi.

**Pralatrexate.** The cytotoxicity induced by pralatrexate can be 10 times greater than that of methotrextate, allowing acquired tumor resistances to be overcome. The agent has been shown to be active in advanced T-cell lymphomas and it is a promising drug for maintenance therapies in CTCL.

**Stem Cell Transplantation**

Autologous stem cell transplantation can achieve high response rates but with immediate relapse (mean time to relapse, < 100 days). This approach is therefore only useful in certain patients as a means to improve quality of life or as a way to buy some time before moving on to other therapies.

Long-term CR has been achieved with allogeneic stem cell transplantation, although mortality is high due mainly to graft-vs-host disease. Indeed, the efficacy of the technique is linked to the appearance of this event, known as a graft-vs-lymphoma effect, in which the donor lymphocytes attack the tumor lymphocytes of the receptor, thereby eliminating them. Currently, regimens are used that are not myeloablative but that are nevertheless cytoreductive prior to transplant, in an attempt to improve response and reduce complications. A recent study lends support to
Table 2  TNMB Staging for Mycosis Fungoides/Sézary Syndrome.

<table>
<thead>
<tr>
<th>Skin</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>T1</td>
<td>Limited patches, papules, and/or plaques covering &lt;10% of the body surface area. Can be</td>
</tr>
<tr>
<td></td>
<td>staged as T1a (only patches) vs T1b (plaques ± patches)</td>
</tr>
<tr>
<td>T2</td>
<td>Patches, papules, and/or plaques covering ≥10% of the body surface area. Can be staged as</td>
</tr>
<tr>
<td></td>
<td>T2a (only patches) vs T2b (plaques ± patches)</td>
</tr>
<tr>
<td>T3</td>
<td>One or more tumors (≥1 cm in diameter)</td>
</tr>
<tr>
<td>T4</td>
<td>Confluence of erythema covering ≥80% of the body surface area</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lymph nodes</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>N0</td>
<td>No abnormal peripheral lymph nodes. Biopsy not required</td>
</tr>
<tr>
<td>N1</td>
<td>Enlarged peripheral lymph nodes, Dutch gr 1 or NCI LN1,2 histology</td>
</tr>
<tr>
<td>N1a</td>
<td>Negative clonality</td>
</tr>
<tr>
<td>N1b</td>
<td>Positive clonality</td>
</tr>
<tr>
<td>N2</td>
<td>Enlarged peripheral lymph nodes, Dutch gr 2 or NCI LN2 histology</td>
</tr>
<tr>
<td>N2a</td>
<td>Negative clonality</td>
</tr>
<tr>
<td>N2b</td>
<td>Positive clonality</td>
</tr>
<tr>
<td>N3</td>
<td>Enlarged peripheral lymph nodes, Dutch gr 3-4, or NCI LN4 positive or negative clonality</td>
</tr>
<tr>
<td>N4</td>
<td>Enlarged peripheral lymph nodes, without histologic confirmation</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Visceral</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>M0</td>
<td>No visceral involvement</td>
</tr>
<tr>
<td>M1</td>
<td>Visceral involvement (histologic confirmation needed and the affected organ should be</td>
</tr>
<tr>
<td></td>
<td>specified)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hematologic</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>B0</td>
<td>Absence of significant hematologic involvement ≤5% atypical lymphocytes (Sézary cells)</td>
</tr>
<tr>
<td>B0a</td>
<td>Negative clonality</td>
</tr>
<tr>
<td>B0b</td>
<td>Positive clonality</td>
</tr>
<tr>
<td>B1</td>
<td>Low hematologic involvement: &gt;5% peripheral lymphocytes are atypical (Sézary cells)</td>
</tr>
<tr>
<td></td>
<td>but do not meet the criterion for B2</td>
</tr>
<tr>
<td>B1a</td>
<td>Negative clonality</td>
</tr>
<tr>
<td>B1b</td>
<td>Positive clonality</td>
</tr>
<tr>
<td>B2</td>
<td>Extensive hematologic involvement: ≥1000/mm³ Sézary cells with positive clonality</td>
</tr>
</tbody>
</table>

In blood, Sézary cells are defined as lymphocytes with highly convoluted cerebriform nuclei. If Sézary cells cannot be used establish the tumor level B2, then 1 of the following modified criteria of the ISCL can be used along with a positive clonal rearrangement in the T-cell receptor: 1) CD4⁺ or C3⁺ expansion with a CD4/CD8 ratio of 10 or more; 2) CD4⁺ expansion with abnormal immunophenotype including loss of CD7 or CD26.

T-cell clonality is defined by a polymerase chain reaction analysis or southern blotting of the gene that encodes the T-cell receptor. Abbreviations and definitions: Dutch, criteria established by the Dutch Cutaneous Lymphomas Group; ISCL, International Society of Cutaneous Lymphomas.

Table 3  Clinical Staging and Classification of Mycosis Fungoides and Sézary Syndrome.

<table>
<thead>
<tr>
<th></th>
<th>T</th>
<th>N</th>
<th>M</th>
<th>B</th>
</tr>
</thead>
<tbody>
<tr>
<td>IA</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0.1</td>
</tr>
<tr>
<td>IB</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0.1</td>
</tr>
<tr>
<td>II</td>
<td>1-2</td>
<td>1,2</td>
<td>0</td>
<td>0.1</td>
</tr>
<tr>
<td>IIB</td>
<td>3</td>
<td>0-2</td>
<td>0</td>
<td>0.1</td>
</tr>
<tr>
<td>III</td>
<td>4</td>
<td>0-2</td>
<td>0</td>
<td>0.1</td>
</tr>
<tr>
<td>IIIA</td>
<td>4</td>
<td>0-2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>IIIIB</td>
<td>4</td>
<td>0-2</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>IVA1</td>
<td>1-4</td>
<td>0-2</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>IVA2</td>
<td>1-4</td>
<td>3</td>
<td>0</td>
<td>0.2</td>
</tr>
<tr>
<td>IVB</td>
<td>1-4</td>
<td>0-3</td>
<td>1</td>
<td>0.2</td>
</tr>
</tbody>
</table>

the role of this treatment for tumoral MF (stage IIB) and SS. The survival rates are significantly higher in patients with second CR, PR, or progression with 3 or fewer lines of prior systemic therapy. Administration of this therapy should therefore not be left too late in the course of the disease. In the short term, it may be the only curative treatment available.

Conclusions

Currently, the aim in the treatment of PCL is to avoid progression to more advanced stages of the disease as, at present, there is no curative treatment available. There are no comparative studies between different systemic treatments in patients with advanced PCL, and so treatment in these patients is not at all protocolized. There is still much debate concerning the management of this disease, and so a conservative or start low go slow approach is recommended. Tables 2–8 summarize the
Table 4  TNM Classification for Lymphomas Other Than Mycosis Fungoides/Sézary Syndrome.

<table>
<thead>
<tr>
<th>T</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>T₁:</td>
<td>solitary skin lesion</td>
</tr>
<tr>
<td>T₁a:</td>
<td>solitary lesion &lt; 5 cm diameter</td>
</tr>
<tr>
<td>T₁b:</td>
<td>solitary lesion &gt; 5 cm diameter</td>
</tr>
<tr>
<td>T₂:</td>
<td>multiple skin lesions in 1 body region or 2 contiguous regions</td>
</tr>
<tr>
<td>T₂a:</td>
<td>all disease encompassed in 1 body region &lt; 15 cm diameter</td>
</tr>
<tr>
<td>T₂b:</td>
<td>all disease encompassed in 1 body region &gt; 15 cm and &lt; 30 cm in diameter</td>
</tr>
<tr>
<td>T₂c:</td>
<td>all disease encompassed in 1 body region &gt; 30 cm diameter</td>
</tr>
<tr>
<td>T₃:</td>
<td>generalized cutaneous involvement</td>
</tr>
<tr>
<td>T₃a:</td>
<td>multiple lesions affecting 2 noncontiguous body regions</td>
</tr>
<tr>
<td>T₃b:</td>
<td>multiple lesions affecting more than 3 body regions</td>
</tr>
<tr>
<td>N</td>
<td></td>
</tr>
<tr>
<td>N₀:</td>
<td>no clinical or pathologic lymph node involvement</td>
</tr>
<tr>
<td>N₁:</td>
<td>involvement of 1 peripheral lymph node region that drains a region of skin involvement</td>
</tr>
<tr>
<td>N₂:</td>
<td>involvement of 2 or more peripheral lymph node regions or a lymph node region that does not drain a region of skin involvement</td>
</tr>
<tr>
<td>N₃:</td>
<td>involvement of central lymph nodes</td>
</tr>
<tr>
<td>M</td>
<td></td>
</tr>
<tr>
<td>M₀:</td>
<td>no evidence of extracutaneous non-lymph-node disease</td>
</tr>
<tr>
<td>M₁:</td>
<td>extracutaneous non-lymph-node disease</td>
</tr>
</tbody>
</table>

Table 5  Recommendations of the European Organisation for Treatment and Research of Cancer on the Treatment of Mycosis Fungoides (MF).

<table>
<thead>
<tr>
<th>MF IA-IIA</th>
<th>MF IIB</th>
<th>MF III</th>
<th>MF IVA-IVB</th>
</tr>
</thead>
<tbody>
<tr>
<td>First-line</td>
<td>PUVA</td>
<td>IFN-α + PUVA</td>
<td>IFN-α + PUVA</td>
</tr>
<tr>
<td></td>
<td>UV-B (patch lesions)</td>
<td>TSEB, radiotherapy</td>
<td>TSEB, radiotherapy</td>
</tr>
<tr>
<td></td>
<td>Topical</td>
<td>IFN-α + retinoids</td>
<td>IFN-α</td>
</tr>
<tr>
<td></td>
<td>Corticosteroids</td>
<td>Bexarotene + PUVA</td>
<td>MTX</td>
</tr>
<tr>
<td></td>
<td>Local radiotherapy</td>
<td></td>
<td>TSEB, radiotherapy</td>
</tr>
<tr>
<td></td>
<td>TSEB (&lt; 3 treatments)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carmustine</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nitrogen mustard</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bexarotene</td>
<td>Oral bexarotene</td>
<td>Oral bexarotene</td>
</tr>
<tr>
<td></td>
<td>IFN-α</td>
<td>Oral bexarotene</td>
<td>Chemotherapy</td>
</tr>
<tr>
<td></td>
<td>IFN-α + retinoids</td>
<td>Chemotherapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Denileukin dixitox</td>
<td>Denileukin dixitox</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Low-dose MTX</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IFN-α + PUVA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Retinoid + PUVA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bexarotene + PUVA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Second-line

Abbreviations: ECP, extracorporeal photopheresis; IFN-α: interferon alfa; MTX, methotrexate; PUVA, psoralen + UV-A; TSEB, total skin electron beam.
Treatment of Cutaneous Lymphomas: an Update

Table 6  Recommendations of the European Organisation for Treatment and Research of Cancer on the Treatment of Sézary Syndrome.

<table>
<thead>
<tr>
<th>First-line</th>
<th>Second-line</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extracorporeal photophoresis</td>
<td>Oral bexarotene</td>
</tr>
<tr>
<td>IFN-α</td>
<td>Chemotherapy</td>
</tr>
<tr>
<td>Denileukin diftitox</td>
<td>Alemtuzumab</td>
</tr>
<tr>
<td>Chlorambucil + prednisone</td>
<td>MTX</td>
</tr>
</tbody>
</table>

Abbreviations: IFN-α, interferon alfa; MTX, methotrexate.

Table 7  Recommendations of the European Organisation for Research and Treatment of Cancer on the Treatment of Cutaneous B-Cell Lymphoma (CBCL).

<table>
<thead>
<tr>
<th>Type of CBCL/Extension</th>
<th>First-Line Treatment</th>
<th>Alternative Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solitary/localized MZ CBCL</td>
<td>Local radiotherapy</td>
<td>IFN-α IL</td>
</tr>
<tr>
<td></td>
<td>Excision</td>
<td>Rituximab IL</td>
</tr>
<tr>
<td></td>
<td>Antibiotics</td>
<td>Corticosteroides IL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IFN-α IL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rituximab IL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Corticosteroides IL or topical</td>
</tr>
<tr>
<td>Multifocal MZ CBCL</td>
<td>Local radiotherapy</td>
<td>IFN-α IL</td>
</tr>
<tr>
<td></td>
<td>Excision</td>
<td>Rituximab IL</td>
</tr>
<tr>
<td></td>
<td>Watchful waiting</td>
<td>(R-CVP/CHOP) in exceptional cases or extracutaneous diseases</td>
</tr>
<tr>
<td></td>
<td>Chlorambucil</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rituximab IV</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antibiotics</td>
<td></td>
</tr>
<tr>
<td>Solitary/localized FC CBCL</td>
<td>Local radiotherapy</td>
<td>IFN-α IL</td>
</tr>
<tr>
<td></td>
<td>Excision</td>
<td>Rituximab IV</td>
</tr>
<tr>
<td></td>
<td>Watchful waiting</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Local radiotherapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rituximab IV</td>
<td></td>
</tr>
<tr>
<td>Solitary/localized CBCL, leg-type</td>
<td>R-CHOP + radiotherapy</td>
<td></td>
</tr>
<tr>
<td>Multifocal CBCL, leg-type</td>
<td>R-CHOP</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CHOP, cyclophosphamide, vincristine, prednisone, and doxorubicin; CVP, cyclophosphamide, vincristine, and prednisone; IFN-α, interferon alfa; IL, intralesional; IV, intravenous; MZ, mantle-zone.

a In the event of evidence of Borrelia burgdorferi infection.

b Other appropriate single-agent or combined chemotherapies for low-grade B-cell lymphomas.

Table 8  Treatment of CD30+ Cutaneous T-Cell Lymphoma (CTCL).

<table>
<thead>
<tr>
<th>First-Line</th>
<th>Second-Line</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymphomatoid papulosis</td>
<td></td>
</tr>
<tr>
<td>Solitary lesion or limited number of lesions</td>
<td>No treatment (watchful waiting)</td>
</tr>
<tr>
<td>Generalized lesions</td>
<td>Topical corticosteroids</td>
</tr>
<tr>
<td></td>
<td>MTX</td>
</tr>
<tr>
<td></td>
<td>NH₂, BCNU</td>
</tr>
<tr>
<td>CD30+ anaplastic large cell lymphoma</td>
<td></td>
</tr>
<tr>
<td>Solitary lesion</td>
<td>Excision</td>
</tr>
<tr>
<td></td>
<td>Radiotherapy</td>
</tr>
<tr>
<td></td>
<td>MTX</td>
</tr>
<tr>
<td></td>
<td>Radiotherapy</td>
</tr>
<tr>
<td>Multiple lesions</td>
<td>MTX</td>
</tr>
</tbody>
</table>

Abbreviations: BCNU, carmustine; CHOP, cyclophosphamide, vincristine, prednisone, and doxorubicin; HDAC, histone deacetylase inhibitors; IFN-α, interferon alfa; MTX, methotrexate; NH₂, nitrogen mustard; PUVA, psoralen + UV-A.
recommendations of the EORTC consensus on treatment as well as staging. The recommendations of the EORTC for treatment of CTCL should be reviewed in the light of new emerging therapies.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References


Treatment of Cutaneous Lymphomas: an Update


